Novel Oral Anticoagulants and Food Intake: Does It Matter?
Novel oral anticoagulants vary in bioavailability when taken with or without food.
Artificial Sweeteners-Are They Better Than Sugar?
Artificial sweeteners are associated with both weight gain and weight loss and a counterintuitive effect on human physiology.
President Bush’s Stress Test-and Stent: Guideline-Directed Care?
PCI is not recommended for asymptomatic adults who are highly functional and report no exercise-induced symptoms.
Oral Anticoagulation and Concomitant Use of Aspirin: Analysis of the ORBIT-AF Registry
Bleeding risk is increased in patients receiving oral anticoagulation and concomitant aspirin.
PTSD and Heart Disease: New Data Help Clarify the Connection
Incidence of CHD was more than double in twins diagnosed with PTSD than those without the disorder.
Low-Risk Lifestyle Protects Against Coronary Events, All-Cause Mortality
All-cause mortality was 80% lower among subjects who maintained normal weight, ate moderately, exercised, and did not smoke compared with those who followed none of these habits.
Apixaban: Effective in Acute VTE; Lower Risk of Major Bleeding
Oral apixaban for acute VTE was superior to enoxaparin followed by warfarin.
Novel Anticoagulants: Dosing Errors and Solutions
Novel anticoagulants have a half life much shorter than warfarin and so adherence and medication error are significant issues.
From Rivaroxaban to Warfarin: How to Switch, Safely
Oral anticoagulation with rivaroxaban must continue while initiating a switch to warfarin. Duration of overlap will be variable.
Novel Anticoagulants: Evidence-Based Patient Selection
Direct thrombin inhibitor dabigatran or factor Xa inhibitor apixaban or rivaroxaban? All are good choices for specific patient types.
Atherosclerosis: TMAO and Evidence for the “Infectious” Hypothesis
The “infectious” hypothesis of atherosclerosis (including bacterial and viral etiologies) may have new support.
Statins Plus Exercise: New Study Questions the Combination
Simvastatin 40 mg once daily can attenuate increases in cardiorespiratory fitness in response to exercise training.
Bleeding Risk in AF: Tools for Clinical Assessment
HAS-BLED, HEMORRHAGES, OBRI: Risk calculators to assess potential for bleeding in AF patients before anticoagulation.
Periprocedural Dabigatran: Risk for Increased Bleeding, Thromboembolism
Periprocedural dabigatran increases the risk of bleeding and thromboembolic complications compared with warfarin during radiofrequency ablation of AF.
Stress Testing 101
Among many considerations when ordering or interpreting a stress test are the limitations and adequacy of the stress modality (exercise, vasodilator, ionotrope) as well as the imaging modality used. Here, top-line reminders for primary care practice.
When the CHADS2 Score = 1: Will Aspirin Do or Is Warfarin Indicated?
The CHA2DS2-VASc score improves risk determination by incorporating age 65 to 74 years, female sex, and history of vascular disease.
Eplerenone Reduces Atrial Fibrillation Incidence in Heart Failure Patients
Aldosterone antagonists, eg, eplerenone, decrease adverse cardiovascular outcomes in patients with HF and AF.
HIV Severity Is Associated With AF Risk
CD4+ count and viral load were complementary and were independently associated with increased incidence of AF.
Interruption of Rivaroxaban vs Warfarin for AF: A Comparison of Risk
Interruption of anticoagulation with rivaroxaban or warfarin should be bridged with an agent such as low-molecular weight heparin.
When Anticoagulation Isn’t an Option: What to Do?
Could the left atrial appendage closure device, known as the Watchman, become an alternative to oral anticoagulation for select patients? Here, more on the 2 trials that have introduced the possibility.
Women and Heart Disease: Incidence, Prevalence, Progress, and the Future
Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women
The Mediterranean Diet in Primary Cardiovascular Prevention
Patients who consumed a Mediterranean-style diet had a 30% reduction in major cardiovascular events compared with patients who ate a diet low in saturated fat.
Beta-Blockers in Heart Failure Patients With Atrial Fibrillation: Do They Really Save Lives?
A recent meta-analysis of beta-blocker use in patients with HF found that the drugs conferred no reduction in rates of mortality or hospitalization among patients with comorbid AF.
DPP-4 Antagonists: Benefits, Risks, and the Future
Dipeptidyl peptidase-4 inhibitors, of the incretin class of antidiabetes drugs, are weight neutral, avoid hypoglycemia, and result in an average reduction in HbA1c of 0.5% to 1.0%
Yoga and Atrial Fibrillation: Calm for the Heart and the Mind
Patients with documented atrial fibrillation given intensive yoga instruction had a reduction in symptomatic and asymptomatic AF episodes.
Lipid-lowering Injectable Antibodies: The Next Big Thing?
PCSK-9 inhibition in patients with recalcitrant hypercholesterolemia has reaped reductions in LDL-C of up to 85% after the first week of therapy.
AHA 2012 Highlights: Multivitamins, Omega-3s, the Polypill, and More
Platelet function monitoring and adjustment of treatment based on results after coronary stenting does not improve clinical outcomes . . . and other findings from the AHA Scientific Sessions.
Who Needs Beta-Blockers? Analysis Raises Questions
A new analysis of data from a large international registry finds that use of beta-blockers in patients with and without a history of coronary artery disease does not reduce cardiovascular events.
Myocardial Infarction: New Meaning, Same Name
In 2000, MI was defined as any necrosis in the setting of myocardial ischemia. The 2007 update to this definition recognized that different conditions can lead to myocardial necrosis and 5 types of myocardial infarctions were defined.
The “Statin-Intolerant” Patient: Alternative Strategies for Primary Care
In patients deemed statin-intolerant, lifestyle changes and alternative classes of drugs should be pursued to lower LDL-C.